Targeting LIN28: a new hope in prostate cancer theranostics

Future Medicine Ltd
Publication Type:
Journal Article
Future Oncology
Filename Description Size
LIN 28_Cancer theranostics_fon-2021-0247.pdfPublished version3.22 MB
Adobe PDF
Full metadata record
The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.
Please use this identifier to cite or link to this item: